1. Home
  2. URGN vs AISP Comparison

URGN vs AISP Comparison

Compare URGN & AISP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • URGN
  • AISP
  • Stock Information
  • Founded
  • URGN 2004
  • AISP 2006
  • Country
  • URGN United States
  • AISP United States
  • Employees
  • URGN N/A
  • AISP N/A
  • Industry
  • URGN Biotechnology: Pharmaceutical Preparations
  • AISP Blank Checks
  • Sector
  • URGN Health Care
  • AISP Finance
  • Exchange
  • URGN Nasdaq
  • AISP Nasdaq
  • Market Cap
  • URGN 831.6M
  • AISP 166.9M
  • IPO Year
  • URGN 2017
  • AISP N/A
  • Fundamental
  • Price
  • URGN $18.90
  • AISP $5.09
  • Analyst Decision
  • URGN Strong Buy
  • AISP Strong Buy
  • Analyst Count
  • URGN 8
  • AISP 1
  • Target Price
  • URGN $29.00
  • AISP $6.00
  • AVG Volume (30 Days)
  • URGN 1.3M
  • AISP 1.3M
  • Earning Date
  • URGN 08-07-2025
  • AISP 08-13-2025
  • Dividend Yield
  • URGN N/A
  • AISP N/A
  • EPS Growth
  • URGN N/A
  • AISP N/A
  • EPS
  • URGN N/A
  • AISP N/A
  • Revenue
  • URGN $91,871,000.00
  • AISP $17,978,226.00
  • Revenue This Year
  • URGN $39.80
  • AISP $34.52
  • Revenue Next Year
  • URGN $108.94
  • AISP $59.54
  • P/E Ratio
  • URGN N/A
  • AISP N/A
  • Revenue Growth
  • URGN 8.98
  • AISP N/A
  • 52 Week Low
  • URGN $3.42
  • AISP $1.90
  • 52 Week High
  • URGN $19.36
  • AISP $7.66
  • Technical
  • Relative Strength Index (RSI)
  • URGN 75.30
  • AISP 43.11
  • Support Level
  • URGN $17.68
  • AISP $5.34
  • Resistance Level
  • URGN $19.36
  • AISP $5.94
  • Average True Range (ATR)
  • URGN 1.05
  • AISP 0.41
  • MACD
  • URGN 0.27
  • AISP -0.06
  • Stochastic Oscillator
  • URGN 92.16
  • AISP 13.57

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

About AISP Airship AI Holdings Inc.

Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.

Share on Social Networks: